Overview
An integrated pharmaceutical manufacturer and exporter with full WHO-GMP and ISO certifications. It expanded internationally by 2012, with footprints in more than 10 countries across the Philippines, Myanmar, Georgia, Afganistan and several markets in Africa. The company maintains a registered product portfolio exceeding 1,400 approved products, and an additional ~1,300 products currently awaiting approval in different markets. The production facility is situated on 3 Bigha (≈ ~1.2 acres) of land, of which ~75% is built up, resulting in ~90,000 sq-ft of operational area.Installed capacities are : Tablet manufacturing: 100 million units/month, Capsules: 15 million units/month, Injectable vials: 2 million vials/month, Liquids: 1.5 million bottles/month, Ointments/tubes: 1 million units/month. Presently the unit is running only at 40% utilization.
Owned Pharmaceutical Industry Formulation
Business Details
2006
Year of Establishment
150
No. of Employees
Running Profitable
Current Status of Business
YesBusiness Relocatable
OwnedProperty Type
3 Crs Property Value
Agriculture
Property Classification
Describe Property
3 BIGHA AGRICULTURE LAND CONVERTED INTO INDUSTRIAL LAND
Competition / Market
Domestic operations with a PAN-India franchise network. Key therapeutic focus: ophthalmology, dermatology, cardiovascular. Exports to over 10 countries including Georgia, Nigeria, Uzbekistan, Philippines, Tajikistan, Yemen and Iraq 1,400+ product registered with ~150 awaiting approval. Field presence in 25+ countries supporting market expansion.
Products & Services
Tablet Icon → 100 Million units/month Capsule Icon → 15 Million units/month Injectable Vial Icon → 2 Million vials/month Liquid Bottle Icon → 1.5 Million bottles/month Ointment Tube Icon → 1 Million units/month
Growth Potential
o By 2012: Began international expansion into countries such as Philippines, Myanmar, Georgia, plus Africa, – over 10 countries globally. o Registered with a sizeable product portfolio: over 1,400 products with another ~1,300 awaiting approval across markets o Visionary targets: contract manufacturing business size of ₹100 crore at one point, aiming for ₹1,000 crore by 2030. o CSR(Corporate Social Responsibility) and community works: eye camps, blood donation, rural development, free patient accommodations, etc
Reason For Sale
TO RELOCATE
Financial Details
EBITDA :-
N.A
PAT :-
N.A
Debt :-
N.A
How the Acquisition Process Works
- 01Contact SellerContact Seller
- 02Teaser/Information MemorandumTeaser/Information Memorandum
- 03Valuation ReportValuation Report
- 04FinancialsFinancials
- 05Schedule an Advisory MeetingBook Your Consultation